PIK3CB and acute lymphoblastic leukemia: The use of MAPK-ERK kinase (MEK) inhibitors and PI3K inhibitors has been proposed as a targeted therapy for the Ras/Raf/MEK/ERK signaling pathway in ALL [23,32].